AIMS: Data on HER-2/neu overexpression, its correlation to prognosis and the success of treatment with Herceptin((R)) in ovarian carcinomas are scarce and contradictory. Therefore we assessed HER-2/neu expression and amplification in a large series of ovarian tumours by using tissue microarrays (TMAs). METHODS AND RESULTS: Two TMAs containing 173 invasive carcinomas, 36 borderline tumours, 20 granulosa cell tumours, 14 carcinosarcomas, 11 benign cystadenoms and eight other pelvic tumours were constructed to assess HER-2/neu gene amplification by fluorescence in-situ hybridization (FISH) and immunohistochemistry. Immunohistochemistry was successful in 94.3%; 81.8% were HercepTest negative, 11.3% were scored as 1+, 4.1% as 2+ and 2.8% as 3+, including 3.1% of invasive carcinomas, 2.8% of borderline tumours and 7.7% of carcinosarcomas; 83.6% could be analysed successfully by FISH revealing no aberration in 75.8%, low amplification in 2.7% and high amplification in 3.7% of the cases. In 17.8% monosomy, trisomy, polysomy or deletion could be detected. All cases with high-level amplification had 2+ or 3+ scores on immunohistochemistry. CONCLUSIONS: TMA is a feasible tool to study a large number of ovarian cases. Correlation between immunohistochemistry and FISH was excellent. HER-2/neu overexpression or gene amplification does not correlate with histological tumour type, stage, grade or prognosis.
AIMS: Data on HER-2/neu overexpression, its correlation to prognosis and the success of treatment with Herceptin((R)) in ovarian carcinomas are scarce and contradictory. Therefore we assessed HER-2/neu expression and amplification in a large series of ovarian tumours by using tissue microarrays (TMAs). METHODS AND RESULTS: Two TMAs containing 173 invasive carcinomas, 36 borderline tumours, 20 granulosa cell tumours, 14 carcinosarcomas, 11 benign cystadenoms and eight other pelvic tumours were constructed to assess HER-2/neu gene amplification by fluorescence in-situ hybridization (FISH) and immunohistochemistry. Immunohistochemistry was successful in 94.3%; 81.8% were HercepTest negative, 11.3% were scored as 1+, 4.1% as 2+ and 2.8% as 3+, including 3.1% of invasive carcinomas, 2.8% of borderline tumours and 7.7% of carcinosarcomas; 83.6% could be analysed successfully by FISH revealing no aberration in 75.8%, low amplification in 2.7% and high amplification in 3.7% of the cases. In 17.8% monosomy, trisomy, polysomy or deletion could be detected. All cases with high-level amplification had 2+ or 3+ scores on immunohistochemistry. CONCLUSIONS:TMA is a feasible tool to study a large number of ovarian cases. Correlation between immunohistochemistry and FISH was excellent. HER-2/neu overexpression or gene amplification does not correlate with histological tumour type, stage, grade or prognosis.
Authors: Agnieszka M Rygiel; Francesca Milano; Fiebo J Ten Kate; Jacques J G H M Bergman; Kausillia K Krishnadath Journal: J Oncol Date: 2010-06-09 Impact factor: 4.375
Authors: John Farley; Sartoru Fuchiuji; Kathleen M Darcy; Chunqiao Tian; William J Hoskins; William P McGuire; Parviz Hanjani; David Warshal; Benjamin E Greer; Jerome Belinson; Michael J Birrer Journal: Gynecol Oncol Date: 2009-03-09 Impact factor: 5.482
Authors: Katherine Stemke-Hale; Kristy Shipman; Isidora Kitsou-Mylona; David G de Castro; Vicky Hird; Robert Brown; James Flanagan; Hani Gabra; Gordon B Mills; Roshan Agarwal; Mona El-Bahrawy Journal: Mod Pathol Date: 2012-11-23 Impact factor: 7.842
Authors: Abraham Peedicayil; Robert A Vierkant; Vijayalakshmi Shridhar; Joellen M Schildkraut; Sebastian Armasu; Lynn C Hartmann; Brooke L Fridley; Julie M Cunningham; Catherine M Phelan; Thomas A Sellers; Ellen L Goode Journal: Gynecol Oncol Date: 2009-05-05 Impact factor: 5.482
Authors: Evripidis Lanitis; Denarda Dangaj; Ian S Hagemann; De-Gang Song; Andrew Best; Raphael Sandaltzopoulos; George Coukos; Daniel J Powell Journal: PLoS One Date: 2012-11-26 Impact factor: 3.240
Authors: Yukie Sato-Kuwabara; José I Neves; José H T G Fregnani; Rubens A Sallum; Fernando A Soares Journal: BMC Cancer Date: 2009-01-07 Impact factor: 4.430